PHI News Room
All News and Press Releases
Enter any phrase or word you would like to search for and click .
PostNews: Press Release
New date: Notice of extraordinary general meeting in Phase Holographic Imaging PHI AB 2 September 2024
Phase Holographic Imaging PHI AB (publ), reg. no. 556542-7811 (the “Company”), will hold an extraordinary general meeting on 2 September at 14.00 at the Company’s premises at Skiffervägen 48 in Lund.
PostNews: Press Release
PHI postpones the extraordinary general meeting until September 2, 2024
The Board of Directors of PHI AB has decided to postpone the date of the extraordinary general meeting until September 2, 2024. An updated notice for the extraordinary general meeting will be issued shortly.
PostBlog Post
Interview with John Moore
Meet John Moore, the proposed new board member for PHI. John’s extensive experience and visionary mindset make him an invaluable addition to our team. Let’s dive into his journey and what made him interested in PHI.
PostNews: Press Release
Notice of extraordinary general meeting in Phase Holographic Imaging PHI AB 19 August 2024
Phase Holographic Imaging PHI AB (publ), reg. no. 556542-7811 (the “Company”), will hold an extraordinary general meeting on 19 August at 14:00 at the Company’s premises at Skiffervägen 48 in Lund.
PostNews: Press Release
Board member Leland Foster resigns due to personal reasons
PHI announces the resignation of esteemed board member Leland Foster. Mr. Foster has decided to resign from his position due to his age and his desire to retire from professional commitments. After this, the Board of Directors continues to have a quorum in accordance with the Articles of Association.
PostNews
BioStock: PHI aims for US listing
BioStock has talked to PHI’s CEO, Patrik Eschricht, to learn more about what the dual listing on the US OTCQB market means for the company and its plans for the future.
Company News
Here, you see PHI featured in recent news and find previous CEO commentaries.
BioStock: PHI “We aim to revolutionize the regenerative medicine market“
BioStock talked to PHI’s CEO, Patrik Eschricht, about the eventful past year and his vision for the company’s future within regenerative medicine.
BioStock: PHI’s CEO reflects on the Company’s momentum
BioStock reached out to PHI’s CEO, Patrik Eschricht, to delve into what latest developments have contributed to the heightened enthusiasm surrounding the company.
BioStock: Altium fuels PHI’s forward drive
BioStock connects with Goran Dubravčić, Altium’s CEO and PHI’s newly appointed Chairman of the Board, to explore the current pivotal developments and their impact on PHI’s trajectory.
BioStock: PHI links up with two regenerative medicine networks
BioStock contacted CEO Patrik Eschricht to learn more about the company’s future strategies in regenerative medicine and the pivot toward the clinical market.
